Company intelligence / Profile preview

Imspex Diagnostics

Abercynon, Wales, United Kingdom

Ownership: Private
Development stage: Other

Overview

Imspex Diagnostics has developed and commercialized proprietary GC‑IMS instruments (including BreathSpec) used for non‑invasive analysis of volatile organic compounds in breath for research and emerging clinical diagnostic applications; the company positions its technology as an early warning and diagnostic system but does not present itself as running drug-like clinical trials, rather as validating diagnostic performance and equivalence to traditional invasive sampling.[1][2][3][4][6][8][9]

Therapeutic areas: OtherInfectious Diseases
Modalities: DeviceNon-pharmacological therapy
Industry: Metabolite Diagnostics

Partnerships

G.A.S. mbH (high‑tech analytics developer and manufacturer of GC‑IMS instruments and solutions)[3]

Beyond the preview

Go deeper on Imspex Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Imspex Diagnostics.

Explore the full profile